Tobramycin

Generic Name: Tobramycin

Brand Names: Bethkis, Kitabis, Tobi, Tobi Podhaler Weekly Kit, Tobradex, Tobrex, Zylet, Tobi Podhaler, Vantobra (previously Tobramycin PARI)

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₃₇N_₅O_₉

CAS Number: 32986-56-4

Unique Ingredient Identifier: VZ8RRZ51VK

Background: Aminoglycosides, many of which are derived directly from Streptomyces spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic Pseudomonas aeruginosa infections in cystic fibrosis patients, as P. aeruginosa is n...

Indication: Inhaled tobramycin is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa, but is not recommended in patients under six years of age, those with forced expiratory volume in 1 second (FEV) <25 or >80% predicted, or in those with Burkholderia cepacia.
...

Associated Conditions: Bacterial Peritonitis, Bone Infection, Cystic fibrosis, Pseudomonas aeruginosa infection, Eye Infections, Inflammation of the External Auditory Canal, Intraabdominal Infections, Lower respiratory tract infection bacterial, Meningitis, Bacterial, Ocular Inflammation, Septicemia gram-negative, Skin and Subcutaneous Tissue Bacterial Infections, Corticosteroid-responsive Disorder of the Ophthalmic, Ear infection-not otherwise specified caused by susceptible bacteria, Ocular bacterial infections, Recurrent Complicated Urinary Tract Infection, Steroid-responsive inflammation

Associated Therapies: -

Clinical Trials

Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis

Phase 4

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: tobramycin

First Posted Date: 2012-05-31

Last Posted Date: 2012-07-24

Lead Sponsor: University of Milan

Target Recruit Count: 10

Registration Number: NCT01608555

Locations: 🇮🇹
IRCCS Ospedale Maggiore Policlinico via F. Sforza 35, Milan, Italy

Comparison of 2 Treatment Regimens for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis

Phase 4

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: oral ciprofloxacin plus inhaled colistin
Drug: TOBI

First Posted Date: 2011-07-22

Last Posted Date: 2011-08-04

Lead Sponsor: Universitaire Ziekenhuizen KU Leuven

Target Recruit Count: 61

Registration Number: NCT01400750

Locations: 🇧🇪
Department of pediatrics, CF center Uuiversity Hospital Leuven, Leuven, Belgium

Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaid® in Patients With Cystic Fibrosis

Phase 1

Conditions: Cystic Fibrosis

Interventions: Drug: Tobramycin

First Posted Date: 2011-04-18

Last Posted Date: 2011-04-18

Lead Sponsor: Erempharma

Target Recruit Count: 36

Registration Number: NCT01337219

Locations: 🇫🇷
Centre de Ressource et de Compétence Mucoviscidose Pédiatrique Centre de Référence Mucoviscidose, Lyon, France

Effectiveness Comparison Between the Drugs TOBRACORT® and TOBRADEX® in Reducing the Signs and Symptoms of Acute Bacterial Conjunctivitis

Phase 3

Conditions: Acute Bacterial Conjunctivitis

Interventions: Drug: Tobracort
Drug: Tobradex

First Posted Date: 2010-10-25

Last Posted Date: 2010-10-25

Lead Sponsor: Azidus Brasil

Target Recruit Count: 70

Registration Number: NCT01227915

Locations: 🇧🇷
LAL Clínica Pesquisa e Desenvolvimento Ltda, Valinhos, São Paulo, Brazil

Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.

Phase 3

Completed

Conditions: Purulent Bacterial Conjunctivitis

Interventions: Drug: T1225
Drug: Tobramycin

First Posted Date: 2010-07-02

Last Posted Date: 2014-10-29

Lead Sponsor: Laboratoires Thea

Target Recruit Count: 286

Registration Number: NCT01155999

A Single Arm 48-Week Follow-on Safety Study to a Core Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®

Phase 3

Completed

Conditions: Cystic Fibrosis

First Posted Date: 2010-04-27

Last Posted Date: 2020-07-31

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 209

Registration Number: NCT01111383

Locations: 🇵🇱
I Oddzial Chorob Dzieciecych, Wojewodzki Specjalistyczny Szpital Dzieciecy, Kielce, Poland
🇵🇱
Dzieciecy Szpital Kliniczny Akademii Medycznej, Klinika Chorob Pluc I Reumatologii, Lublin, Poland
🇵🇱
Klinika Pneumonologii i Mukowiscydozy, Instytut Gruzlicy i Chorob Pluc w Rabce Zdroj, Rabka Zdroj, Poland

and more 17 locations